2019 Innovation Fund & TVSF Recipients
Cincinnati Children’s Innovation Ventures is pleased to announce the 2019 recipients of the annual Cincinnati Children’s Innovation Fund and recipients of the state of Ohio’s Third Frontier Technology Validation Start-up Fund (TVSF). In 2019, fifteen projects were funded, eleven by the Innovation Fund and four by TVSF.
Cincinnati Children’s Innovation Fund
Cincinnati Children’s researchers discover dozens of health innovations every year. Whether they are prospective molecular targets for treating or diagnosing disease or concepts for new medical devices, many discoveries enter a critical funding gap after basic research funding drops off and before outside commercial investment. Facilitated by Innovation Ventures, the Innovation Fund is designed to fill that gap and provide promising technologies an improved chance to reach full potential by enabling product development and commercialization. Fifty-eight (58) Innovation Fund projects have been funded since its inception in 2012.
State of Ohio’s Technology Validation Start-up Fund (TVSF)
In 2017, Cincinnati Children’s Innovation Ventures received a $500,000 award from the Ohio Development Services Agency, Ohio Third Frontier Technology Validation and Start-up Fund (TVSF) to support technologies requiring validation/proof to enhance commercial viability. Another $500,000 was received in 2019. Eligible technologies must result in an Ohio-based start-up company, a license to a young Ohio company, or are deemed commercially unfeasible. Selected projects require a 1:1 cash cost share match. To date, 15 TVSF projects have been funded under this mechanism.
Innovation Fund recipients and their respective projects are as follows:
- Sarah Beal, PhD, Division of Behavioral Medicine and Clinical Psychology, Judith Dexheimer, PhD, Emergency Medicine and Biomedical Informatics, and Mary Greiner, MD, General and Community Pediatrics, and “Commercializing the Integrated Data Environment to eNhance ouTcomes In cusTody Youth (IDENTITY)”
- Andrew Herr, PhD and David Hildeman, PhD, Division of Immunobiology, “Lead Optimization of a Bcl2A1 inhibitor to Treat T Cell-mediated Disease”
- Bin Huang, PhD, Division of Biostatistics and Epidemiology, “Informing Clinical Decision with Real World Data – Utility of an Innovative Bayesian Analyses Tool”
- Angela Lorts, MD, Heart Institute, Ventricular Assist Device Program, “Complex Care Education Platform”
- Qing Richard Lu, PhD, Division of Experimental Hematology & Cancer Biology, “Novel Potent Inhibitors of Histone Deacetylase 3 for Treating Myelinating Diseases” (Year Two)
- Punam Malik, MD, Division of Experimental Hematology & Cancer Biology, Cincinnati Comprehensive Sickle Cell Center, “A Novel Way to Improve Gene Editing via Increased Homologous Recombination” (Year Two)
- Nicolas Nassar, PhD, Division of Experimental Hematology & Cancer Biology, “Overcoming TKI-Resistance in High Risk B-ALL” (Year Two)
- Ernest Pedapati, MD, MS, FAAP, Division of Child and Adolescent Psychiatry, Division of Neurology and Christina Gross, PhD, Division of Neurology, “FMR1 Gene Therapy for Fragile X Syndrome”
- Ming Tan, PhD and Xi Jason Jiang, PhD, Division of Infectious Diseases, “A Nanoparticle-Based Dual Vaccine Against Norovirus and Rotavirus”
- Brian Varisco, MD, Division of Critical Care Medicine, “Anti-CELA1 Monoclonal Antibody for the Treatment of α-1 Antitrypsin Deficient Emphysema”
- Anthony Zaya, BSN, RN, Division of Patient Services Administration, “Zoggle: Keeping your Central Line High and Dry”
TVSF recipients and their respective projects are as follows:
- Abby Hess, APRN, DNP, Department of Anesthesiology, “Commercialization of a novel breathing-controlled device/mHealth app that interfaces with anesthesia equipment”
- Ryan Moore, MD, Heart Institute and David Morales, MD, Division of Pediatric Cardiothoracic Surgery, “CorSuite: The Surgical Performance Platform”
- Jing Xiang, MD, PhD, "Wearable Magnetoencephalography (MEG)"
- Assem Ziady, PhD and Rhonda Szczesniak, PhD, "Pre-commercialization validation of biomarkers of lung function decline in CF"
Please contact Ginny Van Horne for additional information on the Innovation Fund or the TVSF Program.